BioSpace News Archive

Samsung Bioepis Co., Ltd. released the second edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States.

REGENXBIO Inc. will announce new interim data from the Phase II AAVIATE® and ALTITUDE® trials of ABBV-RGX-314 suprachoroidal delivery in wet AMD and diabetic retinopathy.

Stryker’s navigation system offers surgeons a comprehensive planning and guidance solution for complex cranial procedures.

Mallia Therapeutics GmbH, a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss, today announced that the newly founded company secured its seed financing.

Nacuity Pharmaceuticals, Inc. today announced that a clinical trial site has been added to its Phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.

Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that BioMarin Pharmaceutical has selected it to dispense ROCTAVIAN™ (valoctocogene roxaparvovec-rvox).

Neurologics, the global pioneer in advanced brain health care, proudly announces the grand opening of its transformative Assessment Center in the vibrant city of Newport Beach.

Pulmatrix, Inc. today announced the submission of an investigational new drug (“IND”) application to the United States Food and Drug for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine (“DHE”), under development to treat acute migraine.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its U.S. businesses have been named a “Best Place to Work for Disability Inclusion” by the Disability Equality Index®, recognized as the most comprehensive benchmarking tool for the Fortune 1000 and Am Law 2001 to measure disability workplace inclusion against competitors.

Bristol Myers Squibb announced that the sub-study of the Phase 3 CheckMate -901 trial met the dual primary endpoints of overall survival and progression-free survival as assessed by Blinded Independent Central Review at final analysis.